The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Seminars in Oncology

• Publication date

  2010-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/j.seminoncol.2010.09.007PMID 21074065
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC).

  2016cited by this paper
• Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma

  2011cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

  2010cited by this paper
• Final results of a phase I study of CTLA-4 blockade in combination with GM-CSF for metastatic castration resistant prostate cancer (mCRPC).

  2010cited by this paper
• Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma

  2010cited by this paper
• Hair depigmentation as an indicator of durable response to CTLA-4 therapy.

  2010cited by this paper
• Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).

  2010cited by this paper
• Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells

  2010cited by this paper
• Treating cancer by targeting the immune system.

  2010cited by this paper
• Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells

  2010cited by this paper
• Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.

  2010cited by this paper
• Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

  2010cited by this paper
• Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).

  2009cited by this paper
• Ipilimumab: controversies in its development, utility and autoimmune adverse events

  2009cited by this paper
• A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

  2009cited by this paper
• Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes

  2009cited by this paper
• Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

  2009cited by this paper
• Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma

  2009cited by this paper
• Anti-CTLA4 antibody-induced lupus nephritis.

  2009cited by this paper
• Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report.

  2009cited by this paper
• Autoimmune Inflammatory Myopathy after Treatment with Ipilimumab

  2009cited by this paper
• An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: Prevention of gastrointestinal perforation and/or colectomy

  2008cited by this paper
• Intertriginous and follicular eruption to anticytotoxic T-lymphocyte antigen 4 monoclonal antibody.

  2008cited by this paper
• A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer

  2007cited by this paper
• Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade

  2007cited by this paper
• Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.

  2007cited by this paper
• Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis

  2007cited by this paper
• Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent.

  2006cited by this paper
• Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.

  2006cited by this paper
• Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

  2005cited by this paper
• Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study

  2005cited by this paper
• Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis.

  2004cited by this paper
• CTLA-4 and its role in autoimmune thyroid disease.

  2003cited by this paper

• Influence of high-fiber diet on ipilimumab-induced gastrointestinal toxicity in metastatic melanoma.

  2025cites this paper
• Regulatory T Cell Depletion in Cancer: Challenges, Opportunities, and Future Directions for Antibody Development.

  2025cites this paper
• Peptide-targeted nanoparticles for tumor therapy.

  2025cites this paper
• Prostate cancer immunotherapy-based strategies: an updated review emphasizing immune checkpoint inhibitors

  2025cites this paper
• Sensitize Tumor Immunotherapy: Immunogenic Cell Death Inducing Nanosystems

  2024cites this paper
• Skin-resident γδ T cells mediate potent and selective antitumor cytotoxicity through directed chemotactic migration and mobilization of cytotoxic granules.

  2024cites this paper
• Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy

  2024cites this paper
• Immunotherapy in oral cancer: Review

  2023cites this paper
• Tumor-resident regulatory T cells in pancreatic cancer express the αvβ5 integrin as a targetable activation marker

  2023cites this paper
• A Curious Case of Gastrointestinal Eosinophilia Induced by Treatment With Immune Checkpoint Inhibitors

  2023cites this paper
• Immunomodulatory Therapy in Head and Neck Squamous Cell Carcinoma: Recent Advances and Clinical Prospects

  2023cites this paper
• Investigation of CTLA4’s Application in Advanced Melanoma with Ipilimumab and Nivolumab

  2022cites this paper
• Clinical Manifestations, Diagnosis, Treatment and Prognosis of Uveitis Induced by Anticancer Drugs: A Review of Literature

  2022cites this paper
• Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer

  2022cites this paper
• Cutaneous adverse events caused by immune checkpoint inhibitors.

  2021cites this paper
• Retinal toxicities of Systemic Anticancer Drugs.

  2021cites this paper
• Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors

  2021cites this paper
• A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors

  2021cites this paper
• Anti-tumor effect of CTLA-4 antibody is independent of checkpoint blockade

  2021cites this paper
• Nanovesicle‐Mediated Targeted Delivery of Immune Checkpoint Blockades to Potentiate Therapeutic Efficacy and Prevent Side Effects

  2021cites this paper
• Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients

  2021cites this paper
• Causes of Pruritus in Patients Treated With Immune Checkpoint Inhibitors for Melanomas or Skin Carcinomas

  2021cites this paper
• Skin Reactions to Immune Checkpoint Inhibitors.

  2021cites this paper
• Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management

  2021cites this paper
• Thyroïde et médicaments

  2020cites this paper
• Skin Reactions to Immune Checkpoint Inhibitors.

  2020cites this paper
• Gastrointestinal Tract Adverse Events.

  2020cites this paper
• Hepatotoxicity induced by PD-1 inhibitors in cancer treatment

  2020influential citation
• Serious complications in a patient with generalized non-small cell lung cancer treated with pembrolizumab

  2020cites this paper
• Engineering Nanoparticles toward the Modulation of Emerging Cancer Immunotherapy

  2020cites this paper
• Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development.

  2020cites this paper
• Managing Checkpoint Inhibitor Symptoms and Toxicity for Metastatic Melanoma

  2020cites this paper
• In situ genetic engineering of tumors for long-lasting and systemic immunotherapy

  2020cites this paper
• Sweet’s syndrome under ipilimumab therapy and a brief comparison of the cases in literature

  2020cites this paper
• The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial

  2020cites this paper
• An In Vitro System Combining Tumor Cells and Lymphocytes to Predict the In Vivo Response of Immunomodulatory Antibodies

  2020cites this paper
• Serious complications in a patient with generalized non-small cell lung cancer treated with pembrolizumab

  2020cites this paper
• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Management of Immunotherapy- Related Toxicities, Version 1.2019

  2019cites this paper
• Adverse Hair Reactions to New Targeted Therapies for Cancer

  2019cites this paper
• Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial

  2019influential citation
• Gross and microscopic changes of liver neoplasms and background hepatic structures following neoadjuvant therapy

  2019cites this paper
• TIDieR checklist evaluation of clinical trial intervention reporting for recent FDA-approved anticancer medications

  2019cites this paper
• Diet-dependent toxicity of ipilimumab in metastatic melanoma.

  2019cites this paper
• Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial

  2019cites this paper
• Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma.

  2019cites this paper
• Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer.

  2019cites this paper
• Granulomatous Reaction in a Patient With Metastatic Melanoma Treated With Ipilimumab: First Case Reported With Isolated Cutaneous Findings.

  2019cites this paper
• Immune checkpoint inhibitor therapy for pediatric cancers: A mini review of endocrine adverse events

  2019influential citation
• Adverse Hair Reactions to New Targeted Therapies for Cancer.

  2019cites this paper
• Macroangiopathy is a positive predictive factor for response to immunotherapy

  2019cites this paper
• Granulomatous Reaction in a Patient With Metastatic Melanoma Treated With Ipilimumab: First Case Reported With Isolated Cutaneous Findings

  2019cites this paper
• Managing Checkpoint Inhibitor Symptoms and Toxicity

  2019cites this paper
• Introductory Chapter: Are We There Yet? The Long and Winding Road to Cancer Immunotherapy

  2019cites this paper
• RGMB enhances the suppressive activity of the monomeric secreted form of CTLA-4

  2019cites this paper
• Immune-mediated Colitis from Dual Checkpoint Inhibitors

  2019cites this paper
• Creatinine kinase elevation and peripheral neuropathy during nivolumab treatment of a patient with metastatic renal cell carcinoma.

  2018cites this paper
• Checkpoint inhibitors: What gastroenterologists need to know

  2018cites this paper
• Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists’ perspective

  2018cites this paper
• Immune Checkpoint Inhibitors-Induced Colitis.

  2018cites this paper
• Emerging application of genomics-guided therapeutics in personalized lung cancer treatment.

  2018cites this paper
• Targeted Therapies in Platinum-Resistant Ovarian Cancer: Advances in Immunotherapy Combination Strategies

  2018cites this paper
• Clinical assessment of immune-related adverse events

  2018cites this paper
• Immune‐related adverse events from combination immunotherapy in cancer patients: A comprehensive meta‐analysis of randomized controlled trials

  2018cites this paper
• Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents

  2018cites this paper
• When worlds collide: Th17 and Treg cells in cancer and autoimmunity

  2018cites this paper
• Drugs and Other Substances Interfering with Thyroid Function

  2018cites this paper
• The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis

  2018cites this paper
• Skin Reactions to Immune Checkpoint Inhibitors.

  2018cites this paper
• The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.

  2018cites this paper
• Quality‐of‐life outcomes in patients with advanced melanoma: A review of the literature

  2017cites this paper
• Intestinal perforation after nivolumab immunotherapy for a malignant melanoma: a case report

  2017cites this paper
• Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab

  2017cites this paper
• Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease.

  2017cites this paper
• Adverse Events in Cancer Immunotherapy.

  2017cites this paper
• Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study

  2017cites this paper
• Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta‐analysis of published data

  2017cites this paper
• Long-term and late treatment consequences: endocrine and metabolic effects

  2017cites this paper
• Acute Oncology Care: A narrative review of the acute management of neutropenic sepsis and immune-related toxicities of checkpoint inhibitors.

  2017cites this paper
• Skin Reactions to Immune Checkpoint Inhibitors.

  2017cites this paper
• From Composition to Cure: A Systems Engineering Approach to Anticancer Drug Carriers.

  2017cites this paper
• Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity

  2017cites this paper
• Metastatic Melanoma Responding to Combination Chemotherapy and Immunotherapy after Progression on Ipilimumab and Nivolumab Immunotherapy

  2017cites this paper
• Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies

  2017cites this paper
• A Case Report of Drug-Induced Myopathy Involving Extraocular Muscles after Combination Therapy with Tremelimumab and Durvalumab for Non-Small Cell Lung Cancer

  2017cites this paper
• Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.

  2017cites this paper
• Von der Zusammensetzung zur Heilung: ein systemtechnischer Ansatz zur Entwicklung von Trägern für Tumortherapeutika

  2017cites this paper
• Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors

  2017cites this paper
• Cytokine-Induced Modulation of Colorectal Cancer

  2016cites this paper
• Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis

  2016influential citation
• Appendiceal Enlargement During Immunotherapy Treatment for Melanoma

  2016cites this paper
• Procédés de traitement d'un cancer positif her2

  2016cites this paper
• Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

  2016cites this paper
• How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know

  2016cites this paper
• Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood

  2016cites this paper
• Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barré syndrome: a case report.

  2016cites this paper
• Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.

  2016cites this paper
• Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease

  2016cites this paper
• Endocrinological side-effects of immune checkpoint inhibitors

  2016cites this paper
• Psychological side-effects of immunotherapies in the treatment of malignant melanoma

  2016cites this paper
• Checkpoint Blockade for the Treatment of Advanced Melanoma.

  2016cites this paper